Shuttle Pharmaceuticals Holdings, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Shuttle Pharmaceuticals Holdings, Inc. on May 21, 2026. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Gaithersburg, MD. As of the record date (March 25, 2026), there were 5,546,309 shares of Common Stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
A quorum was established with 3,375,072 shares represented (approximately 60.85% of outstanding shares). All five proposals presented at the meeting were approved:
- Proposal 1 (Election of Directors): Four nominees (Christopher Cooper, Adam Chambers, George Scorsis, and Angel Liriano) were elected to serve until the 2027 annual meeting.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Forvis Mazars, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (Say on Pay): The advisory vote on executive compensation was approved.
- Proposal 4 (Reverse Stock Split Authorization): Stockholders authorized the Board of Directors to effect one or more reverse stock splits of the Common Stock at a ratio between 1-for-2 and 1-for-150, to be implemented at the Board's discretion.
- Proposal 5 (Adjournment): The proposal to adjourn the meeting was approved, though deemed not necessary as all other proposals passed.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard context of the annual meeting. The approval of the reverse stock split authorization (Proposal 4) indicates a strategic intent to potentially adjust the share structure, which may be relevant to liquidity and trading status.
Key Facts for Investor Verification
- Verify the specific timing and ratio of any reverse stock split implementation, as the Board now has discretion to act between 1-for-2 and 1-for-150.
- Confirm the impact of the reverse stock split on the Company's compliance with Nasdaq listing requirements.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 20, 2026, for detailed executive compensation data referenced in Proposal 3.
- Monitor the Company's cash position and burn rate, as the filing does not disclose current liquidity levels.